Daniel W. Tan
11 Hospital Crescent
Singapore, 169610, Singapore
Singapore, 169610, Singapore
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 180 publications
AI-based augmentation of oncology clinical trials.
Journal: Nature reviews. Clinical oncology
Published: July 16, 2026
DNA and RNA EGFR Variant Allele Fractions and Clinical Outcomes in Lung Adenocarcinoma.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 24, 2026
Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies.
Journal: The Lancet. Respiratory medicine
Published: May 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 26, 2026
Rethinking Molecular Profiling Post First-Line Osimertinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 19, 2026
A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non-small cell lung cancer (NSCLC).
Journal: Science advances
Published: January 21, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 17, 2026
Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 17, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 17, 2025
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
Journal: Nature cancer
Published: August 13, 2025
A systematic literature review and meta-analysis on the efficacy and safety of PD-(L)1 inhibitors for the first- and second-line treatment of locally advanced or metastatic non-small cell lung cancer in Asian and non-Asian patients.
Journal: Translational lung cancer research
Published: June 26, 2025
Last Updated: 09/26/2026